Fampridine Extended-Release Tablets (Fampyra) are a prescription medication used to improve walking ability in patients with multiple sclerosis (MS). Due to its specificity and strict medication requirements, patients must pay attention to the legality of purchase channels, medication effectiveness, and identification of authentic vs. counterfeit drugs when purchasing.
How to Purchase Fampridine Extended-Release Tablets (Fampyra)
Overseas Purchase
Patients may choose to consult and purchase Fampridine Extended-Release Tablets at hospital pharmacies or authorized pharmacies in countries or regions where the drug has been launched.
Since drug prices may be affected by factors such as regional differences and exchange rate fluctuations, patients need to make a budget and plan in advance before purchasing.
Purchase via Medical Service Institutions
Patients can consult domestic overseas medical service institutions that cooperate with international pharmacies or pharmaceutical companies.
These institutions usually provide legal import channels and can offer professional consultation and guidance.
Precautions for Purchasing Fampridine Extended-Release Tablets (Fampyra)
Strictly Follow Medication Indications
Indication restrictions: Only applicable to adult MS patients; clinical evaluation is required to confirm that walking impairment is related to MS.
Contraindication screening: Contraindicated in patients with a history of epilepsy, moderate to severe renal impairment (CrCl ≤ 50 mL/min), or hypersensitivity to 4-aminopyridine.
Verification of Drug Specifications and Packaging
Specifications: Authentic products are 10mg extended-release film-coated tablets, white to off-white and oval-shaped, with "A10" printed on one side.
Packaging information: The outer box should indicate the manufacturer (Acorda Therapeutics), batch number, expiration date, and FDA approval number (if applicable).
Medication Dosage and Monitoring
Dosage limit: The maximum daily dose is 10mg twice a day (12 hours apart); exceeding the dose may trigger epilepsy.
Renal function monitoring: Creatinine clearance (CrCl) must be tested before medication use; patients with mild renal impairment (CrCl 51–80 mL/min) require careful risk assessment.
Drug Interactions
Avoid combined use: Concurrent use with other drugs containing 4-aminopyridine (e.g., fampridine) is prohibited.
OCT2 inhibitors: Drugs such as cimetidine may increase blood drug concentration; patients must inform doctors of all medications they are taking.
How to Identify Authentic vs. Counterfeit Fampridine Extended-Release Tablets (Fampyra)
Inspection of Outer Packaging and Labels
Anti-counterfeiting marks: The packaging of authentic products should be intact, with no signs of damage or tampering; some countries provide anti-counterfeiting QR code verification services.
Production information: Verify the manufacturer’s address and NDC code.
Inspection of Drug Appearance and Texture
Tablet characteristics: Authentic tablets are white to off-white, oval-shaped film-coated tablets, with no cracks or discoloration; the contents are uniform extended-release granules.
Dissolution test: Extended-release tablets should not dissolve quickly in water; rapid disintegration when placed in water may indicate a counterfeit product.
